Loading...
XHKG1789
Market cap713mUSD
Dec 27, Last price  
4.96HKD
1D
-1.00%
1Q
5.08%
IPO
85.77%
Name

AK Medical Holdings Ltd

Chart & Performance

D1W1MN
XHKG:1789 chart
P/E
28.59
P/S
4.76
EPS
0.16
Div Yield, %
1.11%
Shrs. gr., 5y
1.33%
Rev. gr., 5y
12.74%
Revenues
1.09b
+3.97%
148,278,000206,164,000270,777,000372,700,000600,562,000926,705,0001,035,386,000761,441,0001,052,047,0001,093,862,000
Net income
182m
-11.07%
51,721,00064,907,00077,326,000105,376,000144,936,000266,992,000314,007,00092,619,000204,772,000182,104,000
CFO
34m
-86.03%
51,092,00036,302,00069,643,000116,652,000127,992,000144,662,000205,257,000176,621,000242,919,00033,935,000
Dividend
Jun 24, 20240.045 HKD/sh

Profile

AK Medical Holdings Limited, an investment holding company, designs, develops, produces, and markets orthopedic joint implants and related products under the AK Medical brand in China and internationally. It offers knee, hip, and spine replacement implants; and 3D-printed products, such as 3D-printed hip replacement implants, 3D-printed artificial vertebral bodies, and 3D-printed spinal interbody cages. The company also distributes third party orthopedic products; and manufactures surgical instruments and medical irrigators. Its principal customers include distributors, hospitals, physicians and surgeons, and patients. The company was founded in 2003 and is headquartered in Beijing, the People's Republic of China. AK Medical Holdings Limited is a subsidiary of Ximalaya Limited.
URL
https://www.ak-medical.net/index.html
IPO date
Dec 20, 2017
Employees
1,082
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,093,862
3.97%
1,052,047
38.17%
761,441
-26.46%
Cost of revenue
908,749
824,897
667,984
Unusual Expense (Income)
NOPBT
185,113
227,150
93,457
NOPBT Margin
16.92%
21.59%
12.27%
Operating Taxes
49,013
35,518
15,940
Tax Rate
26.48%
15.64%
17.06%
NOPAT
136,100
191,632
77,517
Net income
182,104
-11.07%
204,772
121.09%
92,619
-70.50%
Dividends
(61,509)
(23,962)
(36,694)
Dividend yield
0.88%
0.22%
0.50%
Proceeds from repurchase of equity
8,933
10,774
(49,611)
BB yield
-0.13%
-0.10%
0.67%
Debt
Debt current
35,633
13,500
10,952
Long-term debt
79,120
64,062
72,166
Deferred revenue
13,331
12,351
Other long-term liabilities
64,378
8,324
Net debt
(611,919)
(1,599,175)
(1,352,855)
Cash flow
Cash from operating activities
33,935
242,919
176,621
CAPEX
(183,796)
(121,717)
(76,229)
Cash from investing activities
(318,148)
(82,294)
(297,101)
Cash from financing activities
(14,021)
(36,796)
(100,703)
FCF
198,229
150,524
(137,669)
Balance
Cash
726,672
1,042,422
841,134
Long term investments
634,315
594,839
Excess cash
671,979
1,624,135
1,397,901
Stockholders' equity
1,404,729
1,235,120
1,017,798
Invested Capital
1,868,505
1,020,308
985,866
ROIC
9.42%
19.10%
7.71%
ROCE
7.29%
9.86%
4.57%
EV
Common stock shares outstanding
1,119,189
1,117,457
1,120,594
Price
6.26
-36.06%
9.79
48.33%
6.60
-47.95%
Market cap
7,006,124
-35.96%
10,939,908
47.92%
7,395,921
-47.32%
EV
6,394,205
9,340,733
6,061,527
EBITDA
276,052
307,551
167,615
EV/EBITDA
23.16
30.37
36.16
Interest
1,287
2,174
1,609
Interest/NOPBT
0.70%
0.96%
1.72%